Patient-Partnered Rare Neurodegenerative Disease RFA

About this funding opportunity

This RFA closed on May 24, 2022

SCIENCE GRANT RESOURCES PAGE Patient-Partnered Collaborations for Rare Neurodegenerative Disease

The Chan Zuckerberg Initiative invites applications from collaborative teams bringing together patient-led rare disease organizations and research teams for 4-year research projects aimed at advancing our understanding of the fundamental science of rare diseases. The Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA aims to advance the understanding of the pathophysiology and mechanistic underpinnings of rare neurodegenerative and neurological disorders.

Awards are $2,000,000 USD total costs for four years for each project (distributed amongst research institutions and a patient organization). The award period for each RFA is an initial two years of funding, followed by an additional two years, pending evaluation. Applicants are welcome to apply to both this opportunity and the Patient-Partnered Collaborations for Single-Cell Analysis of Rare Inflammatory Pediatric Disease RFA"); however, the application and scope of work must be distinct.

CZI is hosting a series of workshops to facilitate networking and the creation of new collaborative teams for this RFA. Learn about our grantees.

Download RFA Packet\\ \\ (Opens in a new window) RFA Contact

For administrative and programmatic inquiries, or other questions pertaining to this RFA, please contact sciencegrants@chanzuckerberg.com"). Key Dates

February 1, 2022

Application portal opens

May 24, 2022

Applications due by 5 p.m. Pacific Time

Late October 2022

Earliest notification of decisions (subject to change)

December 1, 2022

Expected start date of award period

Award period and start date: The award period for each RFA is for an initial two years of funding, followed by an additional two years, pending evaluation. The expected start date is December 1, 2022.

IMPORTANT DOCUMENTS:

Application Instructions")

Institutional Approval Form") Overview

Overview

The CZI Neurodegeneration Challenge Network has three key goals:

(1) To make fundamental advances toward understanding neurodegeneration;

(2) To bring new ideas and talent to the field of neurodegeneration; and

(3) To encourage and experiment with a new interdisciplinary, collaborative, and open science research model involving scientists, clinicians, and engineers.

CZI Neurodegeneration Challenge Network

The Neurodegeneration Challenge Network model is built on the vision that progress in solving neurodegenerative diseases will come from bringing new people into the neurodegeneration field from diverse disciplines and expertise; building interdisciplinary collaborations; empowering the broader scientific community with robust tools and platforms, and creating a culture of open science. Scientifically, we aspire to motivate the collective field to shift the approach to neurodegenerative diseases to a framework, where these diseases, currently addressed largely as distinct diseases and problems, are considered more holistically as a class of disorders with common features, mechanisms, and solutions. The Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA extends on this vision by expanding the scope of diseases and biological problems covered within NDCN, and widens the circle of experts and stakeholders to include patient organizations as collaborators, building on learnings from CZI’s Rare as One Network and CZI’s efforts in patient-directed research.

In the three years since launching the Neurodegeneration Challenge Network (NDCN) in 2018, the Network has grown to a thriving collaborative network that includes 56 teams, 108 labs and over 500 affiliated students, postdocs, and staff scientists. We are now pleased to invite applications to join the Neurodegeneration Challenge Network through a new Request for Applications (RFA) and grant program, the Patient-Partnered Collaborations for Rare Neurodegenerative Disease.

Building on the…

Topic areas: Life Sciences and Health, Social Innovation and Community Development.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are accepted on a rolling basis; there is no single fixed deadline.

Who can apply

This opportunity is open to the following applicant types:

• Not specified by the program.

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

Patient-Partnered Rare Neurodegenerative Disease RFA is administered by Chan Zuckerberg Initiative (CZI), listed via Chan Zuckerberg Initiative.